Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
McKinsey
Chinese Patent Office
Covington
Medtronic
Argus Health
Johnson and Johnson
Deloitte
Dow

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,153,192

« Back to Dashboard

Title: Thiophene sulfonamides useful as carbonic anhydrase inhibitors
Abstract:Thiophene sulfonamides and pharmaceutical compositions containing the compounds useful in controlling intraocular pressure are disclosed. Methods for controlling intraocular pressure through administration of the compositions are also disclosed.
Inventor(s): Dean; Thomas R. (Weatherford, TX), Chen; Hwang-Hsing (Fort Worth, TX), May; Jesse A. (Fort Worth, TX)
Assignee: Alcon Laboratories, Inc. (Fort Worth, TX)
Filing Date:Nov 27, 1990
Application Number:07/618,765
Claims:1. A compound selected from the group consisting of:

3,4-Dihydro-2-methyl-4-(2-methyl)propylamino-4H-thieno[3,2-e]-1,2-thiazine- 6-sulfonamide-1,1-dioxide;

3,4-Dihydro-4-methoxy-2-[2-(4-morpholino)ethyl]-4H-thieno[3,2-e]-1,2-thiazi ne-6-sulfonamide-1,1-dioxide,

3,4-Dihydro-4-ethylamino-2-methyl-4H-thieno[3,2-e]-1,2-thiazine-6-sulfonami de-1,1-dioxide;

3,4-Dihydro-4-ethylamino-2-allyl-4H-thieno[3,2-e]-1,2-thiazine-6-sulfonamid e-1,1-dioxide;

3,4-Dihydro-4-ethylamino-2-n-propyl-4H-thieno[3,2-e]-1,2-thiazine-6-sulfona mide-1,1-dioxide;

3,4-Dihydro-4-ethylamino-2-(2-methoxyethyl)-4H-thieno[3,2-e]-1,2-thiazine-6 -sulfonamide-1,1-dioxide; and

3,4-Dihydro-4-hydroxy-2-[2-(4-morpholino)ethyl]-4H-thieno[3,2-e]-1,2-thiazi ne-6-sulfonamide-1,1-dioxide.

2. The compound of claim 1 which is

3,4-Dihydro-4-ethylamino-2-methyl-4H-thieno[3,2-e]-1,2-thiazine-6-sulfonami de-1,1-dioxide.

3. (+)-3,4-Dihy dro-4-ethylamino-2-methyl-4H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-d ioxide.

4. A formulation for controlling intraocular pressure comprising a therapeutically effective amount of the compound of claim 1 in a pharmaceutically acceptable carrier.

5. The formulation of claim 4 wherein the compound concentration is between about 0.1 and 10% by weight.

6. A formulation for controlling intraocular pressure comprising a therapeutically effective amount of the compound of claim 3 in a pharmaceutically acceptable carrier.

7. The formulation of claim 6 wherein the compound concentration is between about 0.1 and 10% by weight.

8. A method for controlling intraocular pressure which comprises topically administering to the affected eye a therapeutically effective amount of the compound of claim 1.

9. A method for controlling intraocular pressure which comprises topically administering to the affected eye a therapeutically effective amount of the compound of claim 3.

10. A method for controlling intraocular pressure which comprises topically administering the formulation of claim 1.

11. A formulation for controlling intraocular pressure, comprising between about 0.25 wt % and 5.0 wt % (+)-3,4-Dihydro-4-ethylamino-2-methyl-4H-thieno[3,2-e]-1,2-thiazine-6-sulf onamide-1,1-dioxide in a pharmaceutically acceptable carrier.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Johnson and Johnson
Harvard Business School
Chubb
Teva
McKesson
Boehringer Ingelheim
Queensland Health
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.